| Rosuvastatin in Diabetic Hemodialysis Patients. | |
| | |
MedLine Citation:
|
PMID: 21566054 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
A randomized, placebo-controlled trial in diabetic patients receiving hemodialysis showed no effect of atorvastatin on a composite cardiovascular endpoint, but analysis of the component cardiac endpoints suggested that atorvastatin may significantly reduce risk. Because the AURORA (A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events) trial included patients with and without diabetes, we conducted a post hoc analysis to determine whether rosuvastatin might reduce the risk of cardiac events in diabetic patients receiving hemodialysis. Among the 731 participants with diabetes, traditional risk factors such as LDL-C, smoking, and BP did not associate with cardiac events (cardiac death and nonfatal myocardial infarction). At baseline, only age and high-sensitivity C-reactive protein were independent risk factors for cardiac events. Assignment to rosuvastatin associated with a nonsignificant 16.2% reduction in risk for the AURORA trial's composite primary endpoint of cardiac death, nonfatal MI, or fatal or nonfatal stroke (HR 0.84; 95% CI 0.65 to 1.07). There was no difference in overall stroke, but the rosuvastatin group had more hemorrhagic strokes than the placebo group (12 versus two strokes, respectively; HR, 5.21; 95% CI 1.17 to 23.27). Rosuvastatin treatment significantly reduced the rates of cardiac events by 32% among patients with diabetes (HR 0.68; 95% CI 0.51 to 0.90). In conclusion, among hemodialysis patients with diabetes mellitus, rosuvastatin might reduce the risk of fatal and nonfatal cardiac events. |
| | |
Authors:
|
Hallvard Holdaas; Ingar Holme; Roland E Schmieder; Alan G Jardine; Faiez Zannad; Gudrun E Norby; Bengt C Fellström; |
Related Documents
:
|
20126854 - Relationship between insulin and hypogonadism in men with metabolic syndrome. 17589594 - Concentrations of urinary phthalate metabolites are associated with increased waist cir... 16570234 - Visceral adipose tissue as an indicator of insulin resistance in nonobese patients with... 11833054 - Evaluation of the quantitative insulin sensitivity check index as an estimate of insuli... 2527704 - Insulin-induced hypoglycaemia and absorption of injected insulin in diabetic patients. 8899294 - Inhibition of insulin receptor signaling by tnf: potential role in obesity and non-insu... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-5-12 |
Journal Detail:
|
Title: Journal of the American Society of Nephrology : JASN Volume: - ISSN: 1533-3450 ISO Abbreviation: - Publication Date: 2011 May |
Date Detail:
|
Created Date: 2011-5-13 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9013836 Medline TA: J Am Soc Nephrol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
*Department of Nephrology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: High Altitude Renal Syndrome (HARS).
Next Document: Anti-Phospholipase A2 Receptor Antibody in Membranous Nephropathy.